» Articles » PMID: 28822050

Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics

Overview
Publisher Current Science
Specialties Hematology
Oncology
Date 2017 Aug 20
PMID 28822050
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Morphologic dysplasia is an important factor in diagnosis of myelodysplastic syndrome (MDS). However, the role of dysplasia is changing as new molecular genetic and genomic technologies take a more prominent place in diagnosis. This review discusses the role of morphology in the diagnosis of MDS and its interactions with cytogenetic and molecular testing. Recent changes in diagnostic criteria have attempted to standardize approaches to morphologic diagnosis of MDS, recognizing significant inter-observer variability in assessment of dysplasia. Definitive correlates between cytogenetic/molecular and morphologic findings have been described in only a small set of cases. However, these genetic and morphologic tools do play a complementary role in the diagnosis of both MDS and other myeloid neoplasms. Diagnosis of MDS requires a multi-factorial approach, utilizing both traditional morphologic as well as newer molecular genetic techniques. Understanding these tools, and the interplay between them, is crucial in the modern diagnosis of myeloid neoplasms.

Citing Articles

Application of Pathomic Features for Differentiating Dysplastic Cells in Patients with Myelodysplastic Syndrome.

Hong Y, Jeong S, Park M, Song W, Lee N Bioengineering (Basel). 2025; 11(12.

PMID: 39768048 PMC: 11673167. DOI: 10.3390/bioengineering11121230.


Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes.

Mukherjee S, Dong W, Schiltz N, Stange K, Cullen J, Gerds A Oncologist. 2023; 28(10):901-910.

PMID: 37120291 PMC: 10546824. DOI: 10.1093/oncolo/oyad114.


A geno-clinical decision model for the diagnosis of myelodysplastic syndromes.

Radakovich N, Meggendorfer M, Malcovati L, Hilton C, Sekeres M, Shreve J Blood Adv. 2021; 5(21):4361-4369.

PMID: 34592765 PMC: 8579270. DOI: 10.1182/bloodadvances.2021004755.

References
1.
Bhasin T, Sharma S, Manjari M, Mannan R, Kansal V, Chandey M . Changes in megakaryocytes in cases of thrombocytopenia: bone marrow aspiration and biopsy analysis. J Clin Diagn Res. 2013; 7(3):473-9. PMC: 3616559. DOI: 10.7860/JCDR/2013/5085.2801. View

2.
Kuriyama K, Tomonaga M, Matsuo T, Ginnai I, Ichimaru M . Diagnostic significance of detecting pseudo-Pelger-Huët anomalies and micro-megakaryocytes in myelodysplastic syndrome. Br J Haematol. 1986; 63(4):665-9. DOI: 10.1111/j.1365-2141.1986.tb07550.x. View

3.
Valent P, Horny H . Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest. 2009; 39(7):548-53. DOI: 10.1111/j.1365-2362.2009.02151.x. View

4.
Schmitz L, McClure J, Litz C, Dayton V, Weisdorf D, Parkin J . Morphologic and quantitative changes in blood and marrow cells following growth factor therapy. Am J Clin Pathol. 1994; 101(1):67-75. DOI: 10.1093/ajcp/101.1.67. View

5.
Cunningham J, Patnaik M, Hammerschmidt D, Vercellotti G . Historical perspective and clinical implications of the Pelger-Hüet cell. Am J Hematol. 2008; 84(2):116-9. DOI: 10.1002/ajh.21320. View